SRRKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Scholar Rock Holding Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$40.24+0.34 (+0.85%)
Close on Oct 19, 2026
- Market cap
- $5.26B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
139M of 122M shares
Institutional holders
306
58 new, 21 sold out
Net institutional buying
7M
In Q2 2026
Insider trades, 12 months
0 buys · 38 sales
Net sold $19.44M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Redmile Group, LLC | 9,885,124 | 9.90% | 13G (passive) amendment | Dec 31, 2024 |
| Siren, L.L.C. | 9,575,013 | 8.00% | 13G (passive) amendment | Jun 30, 2026 |
| Srinivas Akkaraju | 6,991,553 | 7.20% | 13D (active) amendment | Oct 3, 2025 |
| T. Rowe Price Associates, Inc. | 6,206,044 | 5.40% | 13G (passive) amendment | Mar 31, 2026 |
| Wellington Management Group LLP | 5,759,428 | 5.60% | 13G (passive) | Dec 31, 2025 |
| BlackRock, Inc. | 4,962,597 | 6.90% | 13G (passive) | Dec 31, 2023 |
| FMR LLC | 14,114,029 | 15.00% | 13G (passive) amendment | Dec 31, 2024 |
| Artal International Management S.A. | 12,834,446 | 17.40% | 13G (passive) amendment | Dec 31, 2023 |
| Invus Public Equities, L.P. | 10,825,013 | 11.40% | 13G (passive) amendment | Dec 31, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of SRRK | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 17,995,241 | 14.78% | $989.74M | +752,089 | 0.04% |
| Siren, L.L.C. | 9,575,013 | 7.86% | $526.63M | −1,250,000 | 10.66% |
| BlackRock, Inc. | 9,494,084 | 7.80% | $522.17M | +2,024,791 | 0.01% |
| Samsara BioCapital, LLC | 6,897,652 | 5.66% | $379.37M | – | 31.16% |
| Price T Rowe Associates Inc /Md/ | 6,794,837 | 5.58% | $373.72K | +588,219 | 0.04% |
| Wellington Management Group Llp | 6,727,085 | 5.52% | $369.99M | +9,430 | 0.06% |
| Orbis Allan Gray Ltd | 5,933,533 | 4.87% | $326.34M | +1,753,550 | 1.12% |
| Vanguard Capital Management LLC | 4,767,880 | 3.91% | $262.23M | +876,533 | 0.01% |
| State Street Corp | 4,728,681 | 3.88% | $260.08M | +697,364 | 0.01% |
| Redmile Group, LLC | 4,311,092 | 3.54% | $237.11M | −4,755,529 | 15.92% |
| Norges Bank | 2,769,910 | 2.27% | $152.35M | New | 0.02% |
| Geode Capital Management, LLC | 2,753,787 | 2.26% | $151.49M | +604,751 | 0.01% |
| Massachusetts Financial Services Co /Ma/ | 2,607,348 | 2.14% | $143.39M | New | 0.05% |
| Bellevue Group AG | 2,449,547 | 2.01% | $134.73M | −1,135,026 | 2.83% |
| Jennison Associates LLC | 2,358,587 | 1.94% | $129.72M | −981,905 | 0.08% |
| Jupiter Topco LLC | 2,242,106 | 1.84% | $123.28M | New | 0.05% |
| Hood River Capital Management LLC | 2,224,788 | 1.83% | $122.36M | +175,109 | 0.89% |
| Driehaus Capital Management LLC | 2,205,618 | 1.81% | $121.31M | +285,385 | 0.70% |
| Eventide Asset Management, LLC | 2,111,410 | 1.73% | $116.13M | −85,975 | 1.55% |
| Polar Capital Holdings Plc | 1,878,580 | 1.54% | $103.32M | −105,048 | 0.24% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 306 | 139M | 100.0% | 58 / 129 | 83 / 21 | 25M | 18M |
| Q1 2026 | 274 | 134M | 100.0% | 41 / 113 | 78 / 36 | 24M | 8M |
| Q4 2025 | 274 | 124M | 100.0% | 77 / 95 | 68 / 37 | 24M | 16M |
| Q3 2025 | 241 | 117M | 95.8% | 44 / 93 | 64 / 36 | 17M | 11M |
| Q2 2025 | 235 | 110M | 90.5% | 41 / 92 | 70 / 36 | 12M | 8M |
| Q1 2025 | 231 | 107M | 87.5% | 39 / 88 | 69 / 30 | 11M | 9M |
| Q4 2024 | 224 | 104M | 85.7% | 85 / 69 | 60 / 20 | 29M | 13M |
| Q3 2024 | 161 | 89M | 72.9% | 25 / 55 | 55 / 29 | 27M | 18M |
| Q2 2024 | 166 | 86M | 70.5% | 33 / 69 | 45 / 27 | 12M | 11M |
| Q1 2024 | 161 | 85M | 70.1% | 42 / 51 | 47 / 14 | 9M | 6M |
| Q4 2023 | 133 | 82M | 67.4% | 52 / 65 | 10 / 7 | 29M | 1M |
| Q3 2023 | 89 | 54M | 44.3% | 16 / 51 | 15 / 11 | 6M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of SRRK | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Growth Company Fund | 4,515,375 | 3.71% | $222.61M | 0.23% | May 31, 2026 |
| Vanguard Health Care Fund | 3,859,866 | 3.17% | $182.55M | 0.48% | Jul 31, 2026 |
| Vanguard Total Stock Market Index Fund | 3,427,521 | 2.81% | $188.51M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,870,009 | 2.36% | $157.85M | 0.19% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 2,299,437 | 1.89% | $126.47M | 0.86% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2,258,236 | 1.85% | $124.20M | 1.16% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 1,650,449 | 1.36% | $81.37M | 1.55% | May 31, 2026 |
| Eventide Gilead Fund | 1,460,906 | 1.20% | $80.35M | 2.34% | Jun 30, 2026 |
| Fidelity Growth Company K6 Fund | 1,271,656 | 1.04% | $62.69M | 0.23% | May 31, 2026 |
| Fidelity Small Cap Index Fund | 1,222,019 | 1.00% | $57.80M | 0.17% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 1,141,385 | 0.94% | $62.78M | 0.06% | Jun 30, 2026 |
| SMALLCAP World Fund Inc | 1,128,752 | 0.93% | $62.08M | 0.07% | Jun 30, 2026 |
| MFS Mid Cap Growth Fund | 1,118,671 | 0.92% | $55.15M | 0.40% | May 31, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 1,108,147 | 0.91% | $60.95M | 0.62% | Jun 30, 2026 |
| Fidelity Series Growth Company Fund | 1,098,284 | 0.90% | $54.15M | 0.22% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| David Hallal | Chief Executive Officer, Director | 1,844,034 | 1.51% | Sep 23, 2026 |
| Akshay Vaishnaw | President of R&D, Director | 630,542 | 0.52% | Apr 20, 2026 |
| Jay T. Backstrom | CHIEF EXECUTIVE OFFICER, Director | 425,561 | 0.35% | Mar 12, 2025 |
| Keith Woods | Chief Operating Officer | 620,055 | 0.51% | Sep 25, 2026 |
| Vikas Sinha | Chief Financial Officer | 619,856 | 0.51% | Apr 20, 2026 |
| Mo Qatanani | CHIEF SCIENTIFIC OFFICER | 98,645 | 0.08% | Feb 25, 2026 |
| Caryn Parlavecchio | CHRO | 169,087 | 0.14% | Feb 19, 2026 |
| Jing L. Marantz | CHIEF MEDICAL OFFICER | 126,012 | 0.10% | Feb 19, 2026 |
| Junlin Ho | GENERAL COUNSEL | 241,545 | 0.20% | Feb 19, 2026 |
| Tracey Sacco | Chief Commercial Officer | 76,250 | 0.06% | Apr 29, 2025 |
| Erin Moore | Interim PFO and PAO | 96,173 | 0.08% | Mar 25, 2025 |
| Edward H. Myles | COO & CFO | 111,345 | 0.09% | Mar 12, 2025 |
| Joshua Reed | Director | 20,466 | 0.02% | Jul 6, 2026 |
| Katie Peng | Director | 34,322 | 0.03% | Jul 6, 2026 |
| Michael Gilman | Director | 59,554 | 0.05% | Jul 6, 2026 |
| Kristina Burow | Director | 2,460,368 | 2.02% | Jul 6, 2026 |
| Jeffrey S. Flier | Director | 27,871 | 0.02% | Jul 6, 2026 |
| Srinivas Akkaraju | Director | 6,925,623 | 5.69% | Jun 8, 2026 |
| Richard Brudnick | Director | 21,896 | 0.02% | Jun 8, 2026 |
| Siren, L.L.C. | 10% owner | 10,825,013 | 8.89% | Feb 6, 2026 |
| Invus Global Management, LLC | 10% owner | 9,250,005 | 7.60% | Feb 6, 2026 |
| Raymond Debbane | 10% owner | – | – | Feb 6, 2026 |
| Invus Public Equities, L.P. | 10% owner | – | – | Dec 12, 2024 |
| Invus Public Equities Advisors, LLC | 10% owner | 10,850,154 | 8.91% | Dec 12, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Keith Woods Chief Operating Officer | Sep 24, 2026 | Gift | −48,034 | – | – | 572,021 |
| David Hallal Chief Executive Officer, Director | Sep 21, 2026 | Gift | −36,652 | – | – | 1,602,382 |
| Jeffrey S. Flier Director | Jul 1, 2026 | Sale(10b5-1 plan) | −1,470 | $54.24 | $79.73K | 27,871 |
| Jeffrey S. Flier Director | Jul 1, 2026 | Sale(10b5-1 plan) | −15 | $54.88 | $823 | 27,856 |
| Jeffrey S. Flier Director | Jul 1, 2026 | Sale(10b5-1 plan) | −1,568 | $53.53 | $83.94K | 29,341 |
| Kristina Burow Director | Jul 1, 2026 | Sale(10b5-1 plan) | −948 | $54.28 | $51.46K | 114,657 |
| Kristina Burow Director | Jul 1, 2026 | Sale(10b5-1 plan) | −2,105 | $53.49 | $112.60K | 115,605 |
| Michael Gilman Director | Jul 1, 2026 | Sale(10b5-1 plan) | −1,155 | $54.23 | $62.64K | 59,554 |
| Michael Gilman Director | Jul 1, 2026 | Sale(10b5-1 plan) | −1,346 | $53.54 | $72.06K | 60,709 |
| Michael Gilman Director | Jul 1, 2026 | Sale(10b5-1 plan) | −43 | $54.81 | $2.36K | 59,511 |
| Katie Peng Director | Jul 1, 2026 | Sale(10b5-1 plan) | −2,437 | $54.25 | $132.21K | 34,322 |
| Katie Peng Director | Jul 1, 2026 | Sale(10b5-1 plan) | −21 | $54.96 | $1.15K | 34,301 |
| Katie Peng Director | Jul 1, 2026 | Sale(10b5-1 plan) | −2,988 | $53.56 | $160.04K | 36,759 |
| Joshua Reed Director | Jul 1, 2026 | Sale(10b5-1 plan) | −2,105 | $53.50 | $112.62K | 20,466 |
| Joshua Reed Director | Jul 1, 2026 | Sale(10b5-1 plan) | −948 | $54.28 | $51.46K | 19,518 |
| Kristina Burow Director | Jun 4, 2026 | Award | +6,839 | – | – | 117,710 |
| Michael Gilman Director | Jun 4, 2026 | Award | +6,839 | – | – | 62,055 |
| Katie Peng Director | Jun 4, 2026 | Award | +6,839 | – | – | 39,747 |
| Jeffrey S. Flier Director | Jun 4, 2026 | Award | +6,839 | – | – | 30,909 |
| Srinivas Akkaraju Director | Jun 4, 2026 | Award | +6,839 | – | – | 27,971 |
| Richard Brudnick Director | Jun 4, 2026 | Award | +6,839 | – | – | 21,896 |
| Joshua Reed Director | Jun 4, 2026 | Award | +6,839 | – | – | 22,571 |
| Kristina Burow Director | Apr 23, 2026 | Option exercise | +28,000 | $4.75 | $133.00K | 56,871 |
| Kristina Burow Director | Apr 23, 2026 | Option exercise | +7,800 | $26.78 | $208.88K | 28,871 |
| Kristina Burow Director | Apr 23, 2026 | Option exercise | +36,000 | $9.11 | $327.96K | 92,871 |
| Kristina Burow Director | Apr 23, 2026 | Option exercise | +18,000 | $8.36 | $150.48K | 110,871 |
| David Hallal Chief Executive Officer, Director | Apr 16, 2026 | Sale | −30,615 | $49.57 | $1.52M | 1,639,034 |
| Keith Woods Chief Operating Officer | Apr 16, 2026 | Sale | −10,220 | $49.57 | $506.61K | 620,055 |
| Akshay Vaishnaw President of R&D, Director | Apr 16, 2026 | Sale | −12,246 | $49.57 | $607.03K | 630,542 |
| Vikas Sinha Chief Financial Officer | Apr 16, 2026 | Sale | −10,410 | $49.57 | $516.02K | 619,856 |
| Mo Qatanani CHIEF SCIENTIFIC OFFICER | Feb 23, 2026 | Sale(10b5-1 plan) | −857 | $47.86 | $41.02K | 98,645 |
| Mo Qatanani CHIEF SCIENTIFIC OFFICER | Feb 23, 2026 | Sale(10b5-1 plan) | −200 | $48.48 | $9.70K | 98,445 |
| Mo Qatanani CHIEF SCIENTIFIC OFFICER | Feb 23, 2026 | Sale(10b5-1 plan) | −7,427 | $46.94 | $348.62K | 99,502 |
| Junlin Ho GENERAL COUNSEL | Feb 17, 2026 | Sale | −9,580 | $46.53 | $445.76K | 241,545 |
| Jing L. Marantz CHIEF MEDICAL OFFICER | Feb 17, 2026 | Sale | −4,157 | $46.53 | $193.43K | 126,012 |
| Caryn Parlavecchio CHRO | Feb 17, 2026 | Sale | −9,035 | $46.53 | $420.40K | 169,087 |
| Mo Qatanani CHIEF SCIENTIFIC OFFICER | Feb 17, 2026 | Sale | −7,989 | $46.53 | $371.73K | 106,929 |
| David Hallal Chief Executive Officer, Director | Feb 9, 2026 | Award | +128,004 | – | – | 1,669,649 |
| Vikas Sinha Chief Financial Officer | Feb 9, 2026 | Award | +47,021 | – | – | 630,266 |
| Jing L. Marantz Chief Medical Officer | Feb 9, 2026 | Award | +34,482 | – | – | 130,169 |
| Akshay Vaishnaw President of R&D, Director | Feb 9, 2026 | Award | +47,021 | – | – | 642,788 |
| Keith Woods Chief Operating Officer | Feb 9, 2026 | Award | +47,021 | – | – | 630,275 |
| Caryn Parlavecchio Chief Human Resources Officer | Feb 9, 2026 | Award | +29,258 | – | – | 178,122 |
| Mo Qatanani Chief Scientific Officer | Feb 9, 2026 | Award | +29,258 | – | – | 114,918 |
| Junlin Ho General Counsel | Feb 9, 2026 | Award | +36,572 | – | – | 251,125 |
| Mo Qatanani CHIEF SCIENTIFIC OFFICER | Jan 22, 2026 | Sale(10b5-1 plan) | −12,779 | $46.85 | $598.70K | 85,660 |
| Mo Qatanani CHIEF SCIENTIFIC OFFICER | Jan 22, 2026 | Sale(10b5-1 plan) | −2,119 | $45.87 | $97.20K | 98,439 |
| Jing L. Marantz CHIEF MEDICAL OFFICER | Jan 16, 2026 | Sale | −5,798 | $44.48 | $257.90K | 95,687 |
| Caryn Parlavecchio CHRO | Jan 16, 2026 | Sale | −6,600 | $44.48 | $293.57K | 148,864 |
| Junlin Ho GENERAL COUNSEL | Jan 16, 2026 | Sale | −8,016 | $44.48 | $356.55K | 214,553 |
| Mo Qatanani CHIEF SCIENTIFIC OFFICER | Jan 16, 2026 | Sale | −8,406 | $44.48 | $373.90K | 100,558 |
| Mo Qatanani CHIEF SCIENTIFIC OFFICER | Jan 14, 2026 | Option exercise | +321 | $7.62 | $2.45K | 110,692 |
| Mo Qatanani CHIEF SCIENTIFIC OFFICER | Jan 14, 2026 | Option exercise | +2,813 | $10.00 | $28.13K | 113,505 |
| Mo Qatanani CHIEF SCIENTIFIC OFFICER | Jan 14, 2026 | Option exercise | +5,893 | $15.75 | $92.81K | 119,398 |
| Mo Qatanani CHIEF SCIENTIFIC OFFICER | Jan 14, 2026 | Option exercise | +1,407 | $18.08 | $25.44K | 110,371 |
| Mo Qatanani CHIEF SCIENTIFIC OFFICER | Jan 14, 2026 | Option exercise | +2,678 | $35.15 | $94.13K | 122,076 |
| Mo Qatanani CHIEF SCIENTIFIC OFFICER | Jan 14, 2026 | Sale(10b5-1 plan) | −13,112 | $45.20 | $592.66K | 108,964 |
| David Hallal Chief Executive Officer, Director | Jan 13, 2026 | Sale | −57,450 | $42.70 | $2.45M | 1,541,645 |
| Vikas Sinha Chief Financial Officer | Jan 13, 2026 | Sale | −16,755 | $42.70 | $715.44K | 583,245 |
| Akshay Vaishnaw President of R&D, Director | Jan 13, 2026 | Sale | −20,438 | $42.70 | $872.70K | 595,767 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Peng Katie Director | Oct 1, 2026 | 1,006 | $48.61K | Oct 1, 2026 | RSU |
| Qatanani Mohammed Officer | Jul 6, 2026 | 11,704 | $639.98K | Jul 6, 2026 | Stock Option Exercise |
| Peng Katie Director | Jul 1, 2026 | 5,446 | $298.39K | Jul 1, 2026 | RSU |
| Gilman Michael Director | Jul 1, 2026 | 2,544 | $139.39K | Jul 1, 2026 | RSU |
| Burow Kristina Director | Jul 1, 2026 | 3,053 | $167.27K | Jul 1, 2026 | RSU |
| S. Flier Jeffrey Director | Jul 1, 2026 | 3,053 | $167.27K | Jul 1, 2026 | RSU |
| Reed Joshua Director | Jul 1, 2026 | 3,053 | $167.27K | Jul 1, 2026 | RSU |
| Qatanani Mohammed Officer | Apr 6, 2026 | 23,408 | $1.17M | Apr 6, 2026 | Stock Option Exercise |
| Qatanani Mohammed Officer | Feb 23, 2026 | 8,484 | $409.95K | Feb 23, 2026 | Restricted Stock Award |
| Qatanani Mohammed Officer | Jan 22, 2026 | 14,898 | $686.05K | Jan 22, 2026 | Restricted Stock Award |
| Peng Katie Director | Dec 16, 2025 | 1,006 | $45.51K | Dec 16, 2025 | RSU |
| Qatanani Mohammed Officer | Dec 4, 2025 | 149,574 | $6.43M | Dec 4, 2025 | Stock Option Exercise |
| Qatanani Mohammed Officer | Sep 22, 2025 | 3,353 | $102.85K | Sep 22, 2025 | Restricted Stock Award |
| Peng Katie Director | Sep 16, 2025 | 1,006 | $32.73K | Sep 16, 2025 | RSU |
| Qatanani Mohammed Officer | Jul 8, 2025 | 24,066 | $853.86K | Jul 8, 2025 | Restricted Stock Award |